Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced it has received ethical approval from Australia’s Bellberry Human Research Ethics Committee (HREC) to initiate a Phase I clinical trial for ASKG315, its recombinant human interleukin-15 (IL-15) prodrug Fc fusion protein. The trial will assess the molecule in patients with advanced malignant solid tumors.
Clinical Trial Approval
ASKG315, developed via Aosaikang’s SmartKine cytokine prodrug platform, will be tested for safety and efficacy in a Phase I study. The prodrug is designed to remain inactive in systemic circulation and activate only within the tumor microenvironment, targeting NK cells and Teff cells.
Mechanism of Action
ASKG315’s tumor-specific activation minimizes systemic toxicity while enhancing immune cell stimulation. Preclinical studies confirmed its high binding activity post-activation and significant tumor growth inhibition across multiple models. The drug also boasts the longest half-life among similar cytokine therapies, enabling longer dosing intervals and cost efficiency.
Company Background
Aosaikang, founded in 2015, focuses on innovative oncology therapies. The ASKG315 trial marks a milestone for its SmartKine platform, which aims to revolutionize cytokine-based cancer treatments.-Fineline Info & Tech
